Evidence map›Paper›PMID 25151644›Full record

ArticleNeurobiology of disease2014

Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.

R P Hulse, N Beazley-Long, J Hua, H Kennedy, J Prager, H Bevan, Y Qiu, E S Fernandes, M V Gammons, K Ballmer-Hofer and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Neurobiology of disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

R P HulsePhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK.
N Beazley-LongPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; School of Life Sciences, The Medical School, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK.
J HuaPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
H KennedyPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
J PragerPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
H BevanPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
Y QiuPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
E S FernandesKing's College London, London SE1 9NH, UK.
M V GammonsPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
K Ballmer-HoferPaul Scherrer Institut, 5232 Villigen, Switzerland.
A C Gittenberger de GrootAnatomy and Embryology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands.
A J ChurchillClinical Sciences, University of Bristol, Bristol BS1 2LX, UK.
S J HarperPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK.
S D BrainKing's College London, London SE1 9NH, UK.
D O BatesCancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK. Electronic address: David.Bates@nottingham.ac.uk.
L F DonaldsonPhysiology and Pharmacology, University of Bristol, Bristol BS8 1TD, UK; School of Life Sciences, The Medical School, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK. Electronic address: Lucy.Donaldson@nottingham.ac.uk.
University of Bristol · GBQueen's Medical Centre · GBKing's College London · GBLeiden University · NLPaul Scherrer Institute · CHUniversity of Nottingham · GB

Funding

Diabetes UK 11/0004192Medical Research Council G1002073Wellcome Trust
6 · The paper itself

Abstract

Vascular endothelial growth factor-A (VEGF-A) is best known as a key regulator of the formation of new blood vessels. Neutralization of VEGF-A with anti-VEGF therapy e.g. bevacizumab, can be painful, and this is hypothesized to result from a loss of VEGF-A-mediated neuroprotection. The multiple vegf-a gene products consist of two alternatively spliced families, typified by VEGF-A165a and VEGF-A165b (both contain 165 amino acids), both of which are neuroprotective. Under pathological conditions, such as in inflammation and cancer, the pro-angiogenic VEGF-A165a is upregulated and predominates over the VEGF-A165b isoform. We show here that in rats and mice VEGF-A165a and VEGF-A165b have opposing effects on pain, and that blocking the proximal splicing event - leading to the preferential expression of VEGF-A165b over VEGF165a - prevents pain in vivo. VEGF-A165a sensitizes peripheral nociceptive neurons through actions on VEGFR2 and a TRPV1-dependent mechanism, thus enhancing nociceptive signaling. VEGF-A165b blocks the effect of VEGF-A165a. After nerve injury, the endogenous balance of VEGF-A isoforms switches to greater expression of VEGF-Axxxa compared to VEGF-Axxxb, through an SRPK1-dependent pre-mRNA splicing mechanism. Pharmacological inhibition of SRPK1 after traumatic nerve injury selectively reduced VEGF-Axxxa expression and reversed associated neuropathic pain. Exogenous VEGF-A165b also ameliorated neuropathic pain. We conclude that the relative levels of alternatively spliced VEGF-A isoforms are critical for pain modulation under both normal conditions and in sensory neuropathy. Altering VEGF-Axxxa/VEGF-Axxxb balance by targeting alternative RNA splicing may be a new analgesic strategy.

Indexed as

Vascular Endothelial Growth Factor AAnimalsAntibodiesBenzofuransDisease Models, AnimalDNA, RecombinantEnzyme InhibitorsGanglia, SpinalHyperalgesiaMaleMiceMice, TransgenicNeural ConductionNeuralgiaPain MeasurementPain Threshold(3aS,4S,9bS)-N-(2-(8-cyano-1-formyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo(3,2-c)quinolin-4-yl)-2-methylpropyl)-4,6-difluorobenzofuran-2-carboxyamideAntibodiesBenzofuransDNA, RecombinantEnzyme InhibitorsQuinolinesRNA, MessengerTRPV1 protein, mouseTRPV Cation ChannelsVascular Endothelial Growth Factor AAlternative mRNA splicingNeuropathyNociceptorsVascular endothelial growth factor A

Identifiers

PMID25151644
PMCPMC4194316
OpenAlexW2026983478

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.